1. EP-1237: Heart dose as a risk factor for dyspnea worsening after multimodality treatment for NSCLC and MPM. (May 2017) Authors: Botticella, A.; Billiet, C.; Defraene, G.; Peeters, S.; Draulans, C.; Nafteux, P.; Vansteenkiste, J.; Nackaerts, K.; Dooms, C.; Deroose, C.; Coolen, J.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EP-1246: Is there a different dose-effect relation between the tumour and involved lymph nodes in NSCLC?. (April 2016) Authors: Van den Bosch, L.; Defraene, G.; Peeters, S.; Dooms, C.; De Wever, W.; Deroose, C.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial. (October 2022) Authors: Goldman, J.; Martínez Bueno, A.; Dooms, C.; Jhaveri, K.; de Miguel, M.J.; Piha-Paul, S.A.; Unni, N.; Mahipal, A.; Suga, J.M.; Naltet, C.; Zick, A.; Antoñanzas Basa, M.; Crown, J.; Chae, Y.K.; DiPrimeo, D.; Eli, L.D.; McCulloch, L.; Mahalingam, D. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OC-0047: PD-L1/PD-L2 gene expression differs in tumor vs. lung tissue in non-small cell lung cancer patients. (April 2016) Authors: Reynders, K.; Wauters, E.; Vansteenkiste, J.; Decaluwé, H.; De Leyn, P.; Nackaerts, K.; Peeters, S.; Dooms, C.; Janssens, W.; Lambrechts, D.; De Ruysscher, D. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-0688: Patterns of LR for stage III N2 NSCLC patients after chemotherapy and surgery: implications for PORT. (April 2016) Authors: Billiet, C.; De Ruysscher, D.; Peeters, S.; Decaluwé, H.; Vansteenkiste, J.; Dooms, C.; Deroose, C.M.; Hendrikx, M.; Mebis, J. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PO-1247 Predictive factors for 90 day mortality in stage III NSCLC patients treated with chemo-radiotherapy. (May 2022) Authors: Lambrecht, M.; Van de Velde, A.; Verfaillie, S.; Defraene, G.; Berkovic, P.; Dooms, C.; Vansteenkiste, J.; Wauters, E. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S1052 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The inner and outer of our thorax: silicone breast implants and pulmonary alveolar proteinosis. Issue 5 (3rd September 2015) Authors: De Backer, H.; Darquennes, K.; Dooms, C.; Yserbyt, J.; Coolen, J.; Verschakelen, J.; Verbeken, E.; Vrints, I.; Wuyts, W. Journal: Acta clinica belgica Issue: Volume 70:Issue 5(2015) Page Start: 384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗